Inter-leg Distance Measurement as a Tool for Accurate Step Counting in Patients with Multiple Sclerosis

Bertuletti, Stefano; Salis, Francesca; Cereatti, Andrea; Angelini, Lorenza; Buckley, Ellen; Nair, Krishnan Padmakumari Sivaraman; Mazzà, Claudia; Croce, Ugo Della

doi:10.1109/embc.2019.8857353

Cited by 3 publications

(2 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The accuracy of state-of-the-art stereophotogrammetric systems is usually <1 mm when more than six cameras are used and the whole volume of capture is properly calibrated before beginning of the experiments [ 48 , 49 ]. The same system will also be used to establish the metrological properties and the accuracy of the DMOs estimated with a wearable multisensor system (INertial module with DIstance Sensors and Pressure insoles, INDIP [ 50 , 51 , 52 ]), which will then be used as a reference for the daily life scenarios. The INDIP system integrates inertial modules, distance sensors and pressure insoles.…”

Section: Resultsmentioning

confidence: 99%

Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes

Viceconti

Penna

Dartee

et al. 2020

Sensors

View full text Add to dashboard Cite

Wearable inertial sensors can be used to monitor mobility in real-world settings over extended periods. Although these technologies are widely used in human movement research, they have not yet been qualified by drug regulatory agencies for their use in regulatory drug trials. This is because the first generation of these sensors was unreliable when used on slow-walking subjects. However, intense research in this area is now offering a new generation of algorithms to quantify Digital Mobility Outcomes so accurate they may be considered as biomarkers in regulatory drug trials. This perspective paper summarises the work in the Mobilise-D consortium around the regulatory qualification of the use of wearable sensors to quantify real-world mobility performance in patients affected by Parkinson’s Disease. The paper describes the qualification strategy and both the technical and clinical validation plans, which have recently received highly supportive qualification advice from the European Medicines Agency. The scope is to provide detailed guidance for the preparation of similar qualification submissions to broaden the use of real-world mobility assessment in regulatory drug trials.

show abstract

Section: Resultsmentioning

confidence: 99%

Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes

Viceconti

Penna

Dartee

et al. 2020

Sensors

View full text Add to dashboard Cite

show abstract

“…Mobilise-D will adopt a multidevice and multisensor system approach that includes multiple IMUs located on different parts of the body, pressure insoles and distance sensors. This novel system, called INDIP (inertial module with distance sensors and pressure insoles) [57], is relatively unobtrusive and allows reference DMO data to be recorded in completely unsupervised conditions. The INDIP reference system is proprietary but for each component commercial alternatives are available.…”

Section: Critical Steps In Mobilise-d To Bring Validated Dmos To Regumentioning

confidence: 99%

A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach

et al. 2020

View full text Add to dashboard Cite

Health care has had to adapt rapidly to COVID-19, and this in turn has highlighted a pressing need for tools to facilitate remote visits and monitoring. Digital health technology, including body-worn devices, offers a solution using digital outcomes to measure and monitor disease status and provide outcomes meaningful to both patients and health care professionals. Remote monitoring of physical mobility is a prime example, because mobility is among the most advanced modalities that can be assessed digitally and remotely. Loss of mobility is also an important feature of many health conditions, providing a read-out of health as well as a target for intervention. Real-world, continuous digital measures of mobility (digital mobility outcomes or DMOs) provide an opportunity for novel insights into health care conditions complementing existing mobility measures. Accepted and approved DMOs are not yet widely available. The need for large collaborative efforts to tackle the critical steps to adoption is widely recognised. Mobilise-D is an example. It is a multidisciplinary consortium of 34 institutions from academia and industry funded through the European Innovative Medicines Initiative 2 Joint Undertaking. Members of Mobilise-D are collaborating to address the critical steps for DMOs to be adopted in clinical trials and ultimately health care. To achieve this, the consortium has developed a roadmap to inform the development, validation and approval of DMOs in Parkinson’s disease, multiple sclerosis, chronic obstructive pulmonary disease and recovery from proximal femoral fracture. Here we aim to describe the proposed approach and provide a high-level view of the ongoing and planned work of the Mobilise-D consortium. Ultimately, Mobilise-D aims to stimulate widespread adoption of DMOs through the provision of device agnostic software, standards and robust validation in order to bring digital outcomes from concept to use in clinical trials and health care.

show abstract

Development Technologies for the Monitoring of Six-Minute Walk Test: A Systematic Review

Pires

Villasana

Sá

et al. 2022

Sensors

View full text Add to dashboard Cite

In the pandemic time, the monitoring of the progression of some diseases is affected and rehabilitation is more complicated. Remote monitoring may help solve this problem using mobile devices that embed low-cost sensors, which can help measure different physical parameters. Many tests can be applied remotely, one of which is the six-minute walk test (6MWT). The 6MWT is a sub-maximal exercise test that assesses aerobic capacity and endurance, allowing early detection of emerging medical conditions with changes. This paper presents a systematic review of the use of sensors to measure the different physical parameters during the performance of 6MWT, focusing on various diseases, sensors, and implemented methodologies. It was performed with the PRISMA methodology, where the search was conducted in different databases, including IEEE Xplore, ACM Digital Library, ScienceDirect, and PubMed Central. After filtering the papers related to 6MWT and sensors, we selected 31 papers that were analyzed in more detail. Our analysis discovered that the measurements of 6MWT are primarily performed with inertial and magnetic sensors. Likewise, most research studies related to this test focus on multiple sclerosis and pulmonary diseases.

show abstract

Inter-leg Distance Measurement as a Tool for Accurate Step Counting in Patients with Multiple Sclerosis

Abstract: This is a repository copy of Inter-leg distance measurement as a tool for accurate step counting in patients with multiple sclerosis.

Cited by 3 publications

References 19 publications

Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes

Toward a Regulatory Qualification of Real-World Mobility Performance Biomarkers in Parkinson’s Patients Using Digital Mobility Outcomes

A Roadmap to Inform Development, Validation and Approval of Digital Mobility Outcomes: The Mobilise-D Approach

Development Technologies for the Monitoring of Six-Minute Walk Test: A Systematic Review

Contact Info

Product

Resources

About